EXACT Sciences Co. (NASDAQ:EXAS) insider Kevin T. Conroy sold 101,488 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the completion of the sale, the insider now directly owns 931,540 shares of the company’s stock, valued at $42,590,008.80. The sale was disclosed in a filing with the SEC, which is accessible through this link.

EXACT Sciences Co. (NASDAQ EXAS) traded up $0.04 on Tuesday, reaching $47.57. 1,876,123 shares of the company traded hands, compared to its average volume of 3,387,089. The company has a market cap of $5,760.00, a P/E ratio of -41.37 and a beta of 0.58. EXACT Sciences Co. has a 52 week low of $18.50 and a 52 week high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

EXAS has been the subject of a number of recent analyst reports. Bank of America upped their price objective on shares of EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Jefferies Group upped their price objective on shares of EXACT Sciences to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Craig Hallum upped their price objective on shares of EXACT Sciences from $46.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Benchmark reaffirmed a “buy” rating and issued a $60.00 price objective (up from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Finally, Canaccord Genuity raised shares of EXACT Sciences to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $52.84.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in EXACT Sciences by 1.7% in the 4th quarter. BlackRock Inc. now owns 7,658,145 shares of the medical research company’s stock worth $402,358,000 after buying an additional 126,513 shares during the period. Lord Abbett & CO. LLC boosted its holdings in EXACT Sciences by 59.1% in the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock worth $83,357,000 after buying an additional 875,527 shares during the period. Carillon Tower Advisers Inc. bought a new position in EXACT Sciences in the 4th quarter worth approximately $66,280,000. Victory Capital Management Inc. boosted its holdings in EXACT Sciences by 82.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock worth $62,499,000 after buying an additional 539,160 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in EXACT Sciences by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 1,098,640 shares of the medical research company’s stock worth $57,722,000 after buying an additional 24,614 shares during the period. 83.12% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Kevin T. Conroy Sells 101,488 Shares of EXACT Sciences Co. (EXAS) Stock” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/13/kevin-t-conroy-sells-101488-shares-of-exact-sciences-co-exas-stock.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.